Trial · NCT04272775
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) | Cohort 1: Ixazomib 4.0 mg | 1 | Participants | ||
| Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) | Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | 1 | Participants | ||
| Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | Cohort 1: Ixazomib 4.0 mg | 7 | Participants | ||
| Number of Participants Who Experienced at Least One Treatment-emergent Adverse Event (TEAE) | Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | 7 | Participants | ||
| Number of Participants With Grade 3 or Higher TEAE Related to Body Weight | Cohort 1: Ixazomib 4.0 mg | 0 | Participants | ||
| Number of Participants With Grade 3 or Higher TEAE Related to Body Weight | Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | 0 | Participants | ||
| Number of Participants With Grade 3 or Higher TEAE Related to Vital Signs | Cohort 1: Ixazomib 4.0 mg | 1 | Participants | ||
| Number of Participants With Grade 3 or Higher TEAE Related to Vital Signs | Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | 0 | Participants | ||
| Number of Participants With Grade 3 or Higher TEAE Related to 12-lead Electrocardiograms (ECGs) | Cohort 1: Ixazomib 4.0 mg | 0 | Participants | ||
| Number of Participants With Grade 3 or Higher TEAE Related to 12-lead Electrocardiograms (ECGs) | Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | 0 | Participants | ||
| Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Cohort 1: Ixazomib 4.0 mg | Grade 4: Neutrophils low | 0 | Participants | |
| Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Grade 4: Neutrophils low | 2 | Participants | |
| Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Cohort 1: Ixazomib 4.0 mg | Grade 4: Leukocytes low | 0 | Participants | |
| Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Grade 4: Leukocytes low | 1 | Participants | |
| Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Cohort 1: Ixazomib 4.0 mg | Grade 4: Lymphocytes low | 3 | Participants | |
| Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Grade 4: Lymphocytes low | 0 | Participants | |
| Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Cohort 1: Ixazomib 4.0 mg | Grade 4: Platelets low | 3 | Participants | |
| Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Grade 4: Platelets low | 2 | Participants | |
| Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Cohort 1: Ixazomib 4.0 mg | Grade 4: Sodium low | 0 | Participants | |
| Number of Participants With Grade 3 or Higher Laboratory Tests Abnormalities | Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone | Grade 4: Sodium low | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04272775/results